KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest & Investment Income (2016 - 2025)

Inovio Pharmaceuticals' Interest & Investment Income history spans 11 years, with the latest figure at $552108.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 50.11% year-over-year to $552108.0; the TTM value through Sep 2025 reached $2.8 million, down 50.76%, while the annual FY2024 figure was $4.8 million, 41.39% down from the prior year.
  • Interest & Investment Income for Q3 2025 was $552108.0 at Inovio Pharmaceuticals, down from $610638.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.8 million in Q4 2023 and bottomed at $552108.0 in Q3 2025.
  • The 3-year median for Interest & Investment Income is $979672.5 (2024), against an average of $1.1 million.
  • The largest YoY upside for Interest & Investment Income was 46.14% in 2025 against a maximum downside of 53.29% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $1.8 million in 2023, then tumbled by 53.13% to $852587.0 in 2024, then plummeted by 35.24% to $552108.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Interest & Investment Income are $552108.0 (Q3 2025), $610638.0 (Q2 2025), and $808077.0 (Q1 2025).